-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Exploring Barriers to Combined-Modality Therapy for LS-SCLC
By Anna Farago, MD, PhD Posted: June 2018 Small cell lung cancer (SCLC) accounts for approximately 15% of all new lung cancer diagnoses in the United States. Approximately 30% of patients with newly diagnosed SCLC have limited-stage (LS) disease based on the Veterans’ Administration Lung Study Group staging system; this means that the radiographically evident…
-
Dr. Howard 'Skip' Burris III Shares His Views on Clinical Trial Eligibility Criteria, Payer Involvement
Posted: June 2018 Howard A. “Skip” Burris III, MD, is the chief medical officer and president of clinical operations at Sarah Cannon, the Cancer Institute of HCA Healthcare, where he leads clinical, strategic, and drug-development initiatives. Dr. Burris also is an associate with Tennessee Oncology, PLLC. In the interview below, Dr. Burris discusses the “extended…
-
FDA Fosters Understanding about Approval Process for Biosimilars
By Leah Christl, PhD, Associate Director for Therapeutic Biologics and Director of the Therapeutic Biologics and Biosimilars Staff, Center for Drug Evaluation and Research, FDA Posted: June 2018 All FDA-approved biologics, including reference and biosimilar products, undergo a thorough evaluation so that patients can be assured of the efficacy, safety, and quality of these products.…
-
Oncologic Biologic Biosimilars Are Coming to Market: Are You Ready?
Biosimilars have proven themselves to the U.S. FDA, but clinicians are still wary. By Leah K. Lawrence Posted: June 2018 Healthcare providers are more than familiar with the use of brand name and generic drugs, but the passage of the Biologics Price Competition and Innovation (BPCI) Act of 2009 introduced a new player in the…
-
Breaking News Briefs
New Lung Cancer Screening Guidelines Will Save Lives Reaction was swift and positive last week to new draft guidelines from the U.S. Preventive Services Task Force lowering the requirements for low dose CT imaging as a screening tool for those at risk for lung cancer. Current recommendations call for low-dose CT scans for 55- to…
-
Breaking News Briefs
Nivolumab in the News The dosing schedule for nivolumab now includes a flat dose of 480 mg infused every 4 weeks (Q4W) for a majority of approved indications, including patients who received prior therapy for metastatic NSCLC. The U.S. Food and Drug Administration (FDA) approval provides an alternative to the previously available option of 240…
-
AACR 2018: First-Line Management of Advanced NSCLC Enters New Era
By Corey Langer, MD, IASLC Lung Cancer News Editor Posted: June 2018 The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189, CheckMate 227 and Impower 150—were presented during a plenary session at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. As of that point, immunotherapy (IO) had…
-
PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD Posted: April 2018 Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement, we struggle with the challenge of how to select the right patients for the right treatment. Patient selection is paramount because only 20% to 30% of patients…
-
2017 Lung Cancer SPORE Workshop
By Roy S. Herbst, MD, PhD The National Cancer Institute’s (NCI’s) Lung Cancer Specialized Programs of Research Excellence (SPORE) and their affiliates met June 21-22, 2017, to discuss current trends in translational lung cancer research, plan collaborations, and design new projects. The event was hosted by Yale Cancer Center, the Yale SPORE in Lung Cancer…
-
FDA’s New Nicotine-Focused Regulatory Framework Supported by Evidence Reviews on Electronic Cigarettes
By K. Michael Cummings, PhD, MPH, andGraham Warren, MD, PhD Posted: April 2018 On July 28, 2017, the U.S. Food and Drug Administration (FDA) announced a new emphasis in the federal government’s regulatory framework toward tobacco product regulation. This new emphasis would focus on nicotine and would support innovations to promote tobacco harm reduction based…